ANIK — Anika Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapHigh Flyer

Annual income statement for Anika Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	115	130	148	156	167
Cost of Revenue
Gross Profit	85.9	69	82.9	93.6	103
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	80.4	159	145	176	254
Operating Profit	34.2	-28.3	2.62	-19.4	-87.6
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	36.1	-28.6	2.43	-18.7	-85.3
Provision for Income Taxes
Net Income After Taxes	27.2	-24	4.13	-14.9	-82.7
Net Income Before Extraordinary Items
Net Income	27.2	-24	4.13	-14.9	-82.7
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	27.2	-24	4.13	-14.9	-82.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.89	0.257	0.57	-1.02	-2.88